Ocera Therapeutics (OCRX) Misses Q4 EPS by 1c

Ocera Therapeutics (NASDAQ: OCRX) reported Q4 EPS of ($0.34), $0.01 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $24 thousand versus the consensus estimate of $10 thousand.

For earnings history and earnings-related data on Ocera Therapeutics (OCRX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• KULR Technology Group (KULR) Misses Q2 EPS by 39c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c